Advertisement

Topics

This Startup Is Developing Finger-Prick Blood Tests, But Don't Call It Theranos 2

04:05 EDT 13 Jul 2018 | Forbes

Sight Diagnostics believes it can succeed where Theranos failed, developing rapid finger-prick blood tests, but it's approach is nothing like that of the failed Silicon Valley startup chronicled in the bestselling book Bad Blood.

Original Article: This Startup Is Developing Finger-Prick Blood Tests, But Don't Call It Theranos 2

NEXT ARTICLE

More From BioPortfolio on "This Startup Is Developing Finger-Prick Blood Tests, But Don't Call It Theranos 2"

Advertisement
Quick Search
Advertisement
Advertisement